SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Thursday after HC Wainwright lowered their price target on the stock from $66.00 to $58.00. HC Wainwright currently has a buy rating on the stock. SpringWorks Therapeutics traded as low as $20.62 and last traded at $20.66, with a volume of 170975 shares changing hands. The stock had previously closed at $21.91.
SWTX has been the topic of a number of other reports. The Goldman Sachs Group lifted their price target on SpringWorks Therapeutics from $43.00 to $49.00 and gave the company a “buy” rating in a report on Thursday, July 20th. Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of SpringWorks Therapeutics in a report on Thursday, November 2nd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $49.17.
Institutional Inflows and Outflows
SpringWorks Therapeutics Trading Down 11.0 %
The stock has a 50-day simple moving average of $24.24 and a 200 day simple moving average of $26.29. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -3.91 and a beta of 0.65.
About SpringWorks Therapeutics
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors.
- Five stocks we like better than SpringWorks Therapeutics
- How to Invest in Pharmaceutical Companies
- Institutional activity provides a bottom for gaming stocks
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- Coca-Cola EuroPacific Partners is a tasty play on Coke
- 3 Small Caps With Big Return Potential
- 3 reasons Qualcomm might be the easiest buy this month
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.